Reply to "Interpretation of Pharmacovigilance Disproportionality Analyses"
- PMID: 37259792
- DOI: 10.1002/cpt.2950
Reply to "Interpretation of Pharmacovigilance Disproportionality Analyses"
Comment on
-
COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study.Clin Pharmacol Ther. 2023 May;113(5):1107-1116. doi: 10.1002/cpt.2866. Epub 2023 Feb 27. Clin Pharmacol Ther. 2023. PMID: 36752604
-
Interpretation of Pharmacovigilance Disproportionality Analyses.Clin Pharmacol Ther. 2023 Oct;114(4):745-746. doi: 10.1002/cpt.2951. Epub 2023 May 30. Clin Pharmacol Ther. 2023. PMID: 37248829 No abstract available.
References
-
- Khouri, C., Fusaroli, M., Salvo, F. & Raschi, E. Interpretation of pharmacovigilance disproportionality analyses. Clin. Pharmacol. Ther. 114, 745-746 (2023).
-
- Prontskus, V. et al. COVID-19 vaccination and the incidence of De novo or recurrent rheumatoid arthritis: a French and international (VigiBase) signal detection study. Clin. Pharmacol. Ther. 113, 1107-1116 (2023).
-
- Mathieu, E. et al. Coronavirus pandemic (COVID-19). Our World Data <https://ourworldindata.org/covid-vaccinations> (2020).
-
- Khouri, C. et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J. Clin. Epidemiol. 134, 14-21 (2021).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
